## Roshni Kulkarni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2094300/publications.pdf

Version: 2024-02-01

76 papers 2,884 citations

28 h-index 53 g-index

78 all docs 78 docs citations

78 times ranked 1752 citing authors

#	Article	IF	CITATIONS
1	Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood, 2014, 123, 317-325.	0.6	403
2	Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood, 2004, 103, 2467-2473.	0.6	225
3	Intracranial and Extracranial Hemorrhages in Newborns With Hemophilia. Journal of Pediatric Hematology/Oncology, 1999, 21, 289-295.	0.3	165
4	Recombinant factorÂVIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophiliaÂA. Journal of Thrombosis and Haemostasis, 2015, 13, 967-977.	1.9	150
5	Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia, 2009, 15, 1281-1290.	1.0	127
6	Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. British Journal of Haematology, 2009, 145, 212-220.	1.2	117
7	Prevalence and risk factors for heart disease among males with hemophilia. American Journal of Hematology, 2005, 79, 36-42.	2.0	115
8	Perinatal management of newborns with haemophilia. British Journal of Haematology, 2001, 112, 264-274.	1.2	98
9	Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. British Journal of Haematology, 2011, 152, 211-216.	1.2	98
10	Renal disease among males with haemophilia. Haemophilia, 2003, 9, 703-710.	1.0	84
11	Astroblastoma: does histology predict biologic behavior?. Journal of Neuro-Oncology, 1998, 40, 59-65.	1.4	76
12	BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. New England Journal of Medicine, 2020, 383, 1018-1027.	13.9	76
13	Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres. Haemophilia, 2011, 17, 6-13.	1.0	71
14	The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Advances, 2018, 2, 2136-2144.	2.5	69
15	Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematology,the, 2017, 4, e75-e82.	2.2	61
16	Results from a large multinational clinical trial (guardianâ,,¢3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia <scp>A</scp> : safety, efficacy and pharmacokinetics. Haemophilia, 2013, 19, 698-705.	1.0	59
17	Therapeutic choices for patients with hemophilia and high-titer inhibitors. American Journal of Hematology, 2001, 67, 240-246.	2.0	58
18	Pediatric Hemophilia: A Review. Seminars in Thrombosis and Hemostasis, 2011, 37, 737-744.	1.5	56

#	Article	IF	Citations
19	Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System. Haemophilia, 2017, 23, 207-214.	1.0	56
20	Current practices regarding newborn intracranial haemorrhage and obstetrical care and mode of delivery of pregnant haemophilia carriers: a survey of obstetricians, neonatologists and haematologists in the United States, on behalf of the National Hemophili. Haemophilia, 1999, 5, 410-415.	1.0	51
21	Thrombotic Storm Revisited: Preliminary Diagnostic Criteria Suggested by the Thrombotic Storm Study Group. American Journal of Medicine, 2011, 124, 290-296.	0.6	45
22	Bleeding disorders in neonates. Haemophilia, 2010, 16, 168-175.	1.0	43
23	Use of telehealth in the delivery of comprehensive care for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2018, 24, 33-42.	1.0	41
24	Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: A White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA. Haemophilia, 2006, 12, 205-211.	1.0	38
25	Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor <scp>VIII</scp> Fc fusion protein. Haemophilia, 2018, 24, 77-84.	1.0	37
26	Women with bleeding disorders. Haemophilia, 2018, 24, 29-36.	1.0	36
27	Improving care and treatment options for women and girls with bleeding disorders. European Journal of Haematology, 2015, 95, 2-10.	1.1	34
28	Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thrombosis and Haemostasis, 2017, 117, 508-518.	1.8	31
29	Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism. Thrombosis Research, 2015, 136, 535-541.	0.8	30
30	Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. American Journal of Hematology, 2001, 68, 184-188.	2.0	29
31	Clinical causes and treatment of the thrombotic storm. Expert Review of Hematology, 2012, 5, 653-659.	1.0	29
32	Longâ€term safety and sustained efficacy for up to 5Âyears of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‥OND extension study. Haemophilia, 2020, 26, e262-e271.	1.0	28
33	Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects. Haemophilia, 2013, 19, 2-10.	1.0	20
34	Challenges in the management of haemophilia on transition from adolescence to adulthood. European Journal of Haematology, 2015, 95, 30-35.	1.1	20
35	Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding. Haemophilia, 2018, 24, 63-69.	1.0	19
36	Differences in Thrombotic Risk Factors in Black and White Women with Adverse Pregnancy Outcome. Thrombosis Research, 2014, 133, 108-111.	0.8	17

#	Article	IF	CITATIONS
37	The spectrum and severity of bleeding in adolescents with low von Willebrand factor–associated heavy menstrual bleeding. Blood Advances, 2020, 4, 3209-3216.	2.5	17
38	Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review. Haemophilia, 2021, 27, 293-304.	1.0	15
39	First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood, 2022, 139, 3699-3707.	0.6	13
40	Central venous catheter infections in pediatric patients $\hat{a} \in \text{``in a community hospital. Infection, } 1988, 16, 86-90.$	2.3	12
41	Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a webâ€based study in the United States and Canada. Haemophilia, 2014, 20, e296-303.	1.0	12
42	Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease. American Journal of Hematology, 2020, 95, 10-17.	2.0	12
43	Neonatal Hemostatic Disorders: Issues and Challenges. Seminars in Thrombosis and Hemostasis, 2016, 42, 741-751.	1.5	10
44	Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor <scp>VIII</scp> Fc fusion protein ( <scp>rFVIIIF</scp> c) in the A‣ONG and Kids Aâ€ <scp>LONG</scp> Studies. Haemophilia, 2017, 23, e39-e42.	1.0	10
45	Medical coâ€morbidities and practice. Haemophilia, 2014, 20, 130-136.	1.0	8
46	Double minute chromosomes. A bone marrow indicator of neuroblastoma metastasis and relapse: Two case reports. Cancer, 1986, 57, 2158-2161.	2.0	7
47	Natural history study of factor IX deficiency with focus on treatment and complications (Bâ€Natural). Haemophilia, 2021, 27, 49-59.	1.0	6
48	Variants in chondroitin sulfate metabolism genes in thrombotic storm. Thrombosis Research, 2018, 161, 43-51.	0.8	5
49	Quality of life in a large multinational haemophilia B cohort (The Bâ€Natural study) – Unmet needs remain. Haemophilia, 2022, 28, 453-461.	1.0	5
50	Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD. Blood Advances, 2021, 5, 2079-2086.	2.5	4
51	Telehematology: Expanding Comprehensive Care for Pediatric Patients with Blood Disorders through Telemedicine at Several Delivery Sites (Medical Homes, Hospital Clinics, Home Setting and Hemophilia) Tj ETQq1	l <b>0.</b> 88431	44gBT /Ove
52	Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. Blood Advances, 2022, 6, 420-428.	2.5	4
53	von Willebrand disease Outreach into Integrated Care Education (VOICE): a call to action. Haemophilia, 2017, 23, e370-e373.	1.0	3
54	Using Geographical Information Systems (GIS) To Examine Associations between Characteristics of Males with Hemophilia and Geographic Distance to Hemophilia Treatment Centers (HTCs) Blood, 2006, 108, 3301-3301.	0.6	3

#	Article	IF	Citations
55	The Coags Uncomplicated App: Fulfilling Educational Gaps Around Diagnosis and Laboratory Testing of Coagulation Disorders. JMIR Medical Education, 2017, 3, e6.	1.2	3
56	Alternative and topical approaches to treating the massively bleeding patient. Clinical Advances in Hematology and Oncology, 2004, 2, 428, 431.	0.3	3
57	Pediatric transfusion therapy: Practical considerations. Indian Journal of Pediatrics, 1999, 66, 307-317.	0.3	2
58	Turoctocog alfa and drug development for hemophilia A. Expert Opinion on Orphan Drugs, 2014, 2, 419-431.	0.5	2
59	Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies. Blood, 2015, 126, 2307-2307.	0.6	2
60	Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies. Blood, 2015, 126, 3543-3543.	0.6	2
61	Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a. Blood, 2016, 128, 3791-3791.	0.6	2
62	Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophilia—Hematology Utilization Group Study Part VII (HUGS VII). Journal of Blood Medicine, 2022, Volume 13, 229-241.	0.7	2
63	Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials. Clinical Investigation, 2015, 5, 755-766.	0.0	1
64	Long Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Children with Hemophilia B: Interim Results of the B-Yond Extension Study. Blood, 2016, 128, 4976-4976.	0.6	1
65	<p>Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study</p> . Journal of Blood Medicine, 2019, Volume 10, 391-398.	0.7	1
66	Quality of Life in Female Adolescents with Bleeding Disorders. , 2020, , 129-137.		1
67	Venous thromboembolism. Indian Journal of Pediatrics, 1999, 66, 163-169.	0.3	0
68	Why plasmaâ€derived factor VIII?. Haemophilia, 2019, 25, e183-e185.	1.0	0
69	Pediatric Hematology and Oncology. , 2010, , 389-451.		0
70	Predictors of Von Willebrand Disease In Children: A Case-Control Study. Blood, 2010, 116, 712-712.	0.6	0
71	Intra-Abdominal Venous Thrombosis: Characteristics of Pediatric and Adult Patients. Blood, 2010, 116, 4219-4219.	0.6	0
72	Continued Transmission of Parvovirus B19 in Plasma-Derived Factor Concentrates After the Implementation of B19 Nucleic Acid Plasma Minipool Screening,. Blood, 2011, 118, 3378-3378.	0.6	0

#	Article	IF	CITATIONS
73	Whole-Exome Sequencing Identifies Novel Risk Variant for Thrombotic Storm. Blood, 2011, 118, 1229-1229.	0.6	O
74	Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A. Blood, 2015, 126, 3520-3520.	0.6	0
75	Clinical Outcomes in Children with Hemophilia B Treated Long Term with rFIXFc: Interim Results of the B-YOND Extension Study. Blood, 2015, 126, 1093-1093.	0.6	O
76	Outcomes of Severe Hemophilia a Patients on Continuous Prophylaxis Relative to Inhibitor Status in the Community Counts Registry. Blood, 2016, 128, 1405-1405.	0.6	0